Pentamidine oral

Drug Profile

Pentamidine oral

Alternative Names: Oral OCZ103; VLX 103

Latest Information Update: 30 May 2016

Price : $50

At a glance

  • Originator Oncozyme Pharma
  • Developer Verlyx
  • Class Antifungals; Antineoplastics; Antiprotozoals; Benzamidines; Sulfonic acids
  • Mechanism of Action Endoexonuclease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatocellular carcinoma
  • Preclinical Alcoholic hepatitis; Non-alcoholic steatohepatitis

Most Recent Events

  • 30 May 2016 Chemical information added
  • 01 Dec 2015 Oncozyme Pharma completes a phase I trial in Hepatocellular carcinoma in Canada (NCT02210182)
  • 25 Sep 2015 Verlyx plans phase II trials for Non-alcoholic steatohepatitis and Alcoholic steatohepatitis (Verlyx website, September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top